William Mann, PhD, MBA, is a biopharma executive with extensive experience in R&D, commercialization, and innovation leadership. They served as President & CEO of Helsinn Therapeutics from 2009 to 2018, transforming the company into a profitable entity. Mann has held various influential roles, including Director of Global Business Development and Licensing at Novartis and President and COO at NeuBase Therapeutics, Inc. Currently, they are a member of the Board of Directors at ARDAN PHARMA and a Senior Technology Manager at TechLink. Mann is also pursuing a Postdoctoral Fellowship in Human Genetics at The Rockefeller University, a PhD in Biochemistry at the University of Aberdeen, and an MBA at Rutgers University.
This person is not in any teams
This person is not in any offices